Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
96results about How to "Good antitumor effect" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibody-drug conjugate
ActiveUS20150297748A1Good antitumor effectImprove securityImmunoglobulins against cell receptors/antigens/surface-determinantsPharmaceutical non-active ingredientsAntiendomysial antibodiesChemical compound
As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula:-L1-L2-LP-NH—(CH2)n1-La-Lb-Lc-wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
Owner:DAIICHI SANKYO CO LTD
Biodegradable polyurethane with amino on side chain and preparation method and application thereof
InactiveCN103172819ARegular structureGood biocompatibility and biodegradabilityOrganic active ingredientsPharmaceutical non-active ingredientsIsocyanateFluorescence
The invention provides biodegradable polyurethane with an amino on the side chain and a preparation method and application thereof, belonging to the field of biomedical materials. Polyurethane is formed by a soft segment and a hard segment, wherein the soft segment is biodegradable polyester diol or biodegradable polyether diol; the hard segment is formed by aliphatic diisocyanate and a chain extender; and the hard segment is provided with the free or protected amino. The biodegradable polyurethane serves as a drug carrier, can wrap drug molecules to form drug carrying microspheres in the nanometer or micrometer scale and can be used for bonding drug molecules, fluorescent molecules and targeted molecules to prepare polyurethane bonded drugs, polyurethane fluorescent probes or polyurethane targeting carriers.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
DSPE-PEG-FA-modified nanometer paclitaxel liposome and preparation method thereof
InactiveCN102188382AHigh encapsulation efficiencyGuaranteed purityOrganic active ingredientsPharmaceutical non-active ingredientsPaclitaxel InjectionDspe peg
The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the phosphatidyl ethanolamine-polyethylene glycol2000-folic acid micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.
Owner:李红霞
Anti-tumor agent
InactiveUS20120077837A1Good antitumor effectImprove anti-tumor effectBiocideAnimal repellantsHalogenEverolimus
A combination therapy for tumor is provided. Disclosed is a method of treating tumor, the method comprises administering to a patient, a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and everolimus represented by Formula (II):wherein R1 is C1-6 alkyl or C3-8 cycloalkyl; R2 is a hydrogen atom or C1-6 alkoxy; and R3 is a hydrogen atom or a halogen atom.
Owner:EISIA R&D MANAGEMENT CO LTD
Anti-her2 antibody-drug conjugate
ActiveUS20160333112A1Good antitumor effectImprove securityOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsDrug conjugationTherapeutic effect
As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2—C(═O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
Owner:DAIICHI SANKYO CO LTD
Application of ingenane diterpene compound in preparation of antitumor drug
ActiveCN104622865AHigh activityGood choiceCarboxylic acid esters separation/purificationChemical recyclingSide effectMedicine
The invention discloses an application of an ingenane diterpene compound in preparation of antitumor drug. The ingenane diterpene compound is one or more of the ingenane diterpene compound shown in a formula (1). The ingenane diterpene compound can obviously inhibit the propagation activity of breast cancer cells, compared with a traditional tumor therapeutic method, tumor inhibitory effect is good, toxic and side effects are little, targeting property is strong, the ingenane diterpene compound has no damage to normal cells, security can be guaranteed at maximum degree, the ingenane diterpene compound provides a latent novel medicine development purpose for treating breast cancer, and can be a further research as an anti-breast cancer candidate medicine.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Preparation of glutamic acid modified polyethylene glycol monostearate and application of glutamic acid modified polyethylene glycol monostearate in target drug transfer
ActiveCN105315455AGentle preparationEasy to manufactureOrganic active ingredientsPharmaceutical non-active ingredientsCell membranePolyethylene glycol
The invention relates to preparation of glutamic acid-polyethylene glycol monostearate and application of the amphipathic target material modified nano-particles in disease target transfer. According to the amphipathic target material, glutamic acid is used as a target head, polyethylene glycol is used for improving the flexibility of the target head, and hydrophobic monostearate is used as an anchoring position with polyglycolic-polylactic acid copolymer. The target material modified nano-particles can be used as a target transfer tool of multiple anti-tumor drugs, and interacts with high-expression big neutral amino acid transporter 1 on a tumor cell membrane by the surface modified glutamic acid, so that the cell uptake and anti-tumor activity of the nano-particles can be effectively improved. The nano-particles have good stability, excellent target performance, can be used in intravenous injection, and have a relatively large market application prospect.
Owner:SHENYANG PHARMA UNIVERSITY
Chimeric antigen receptor (CAR) containing third signal receptor and application of CAR
ActiveCN110615843AIncrease lethalityImprove acceleration performanceVirusesPeptide/protein ingredientsSide effectTumor targeting
Owner:SHANGHAI LONGYAO BIOTECH CO LTD
Antitumor Agent
InactiveUS20190153095A1Good antitumor effectImprove anti-tumor effectImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenCancer cell
Provided is an antitumor agent targeting SIRPα, which inhibits binding between CD47 and SIRPα, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRPα. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRPα protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect. Further, the antitumor agent can effectively exhibit an antitumor action not only on cancer cells expressing SIRPα on a cell surface but also on cancer cells not expressing the SIRPα when used in combination with, for example, an immune checkpoint inhibitor and / or an antibody drug that specifically reacts with a cancer antigen and has ADCC and ADCP activities.
Owner:KOBE UNIV
Demethyl sodium cartharidate medicinal compound and its preparation method and application
InactiveCN1785985AHigh purityGood water solubilityOrganic active ingredientsPowder deliveryWater contentDrug
The present invention discloses a disodium norcantharidinate medicine compound, its preparation method and application. Its molecular formula is C8H8O5Na2, and its molecular weight is 230.2. Said medicine is obtained by using 1 mol of norcantharidin and 2.0-2.5 mol of sodium hydroxide, making them be completely reacted at 2 deg.C-100deg.C, then making evaporation at 100deg.C-200deg.C to remove water content. Said invention also provides the application of said disodium norcantharidinate medicine compound in preparation of medicine for resisting tumor. It can be made into powder injection, liquid injection or transfusion preparation.
Owner:山东山大康诺制药有限公司
Ganoderma lucidum spore powder compound product for improving anti-tumor curative effects and method for preparing ganoderma lucidum spore powder compound product
InactiveCN105267695AImprove anti-tumor efficacyFacilitated releaseOrganic active ingredientsAntinoxious agentsSide effectAdditive ingredient
Owner:安徽千方生物科技有限公司
Recombinant anti-PD-L1 monoclonal antibody
PendingCN110878122AHigh affinityGood antitumor effectImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsComplementarity determining regionAntiendomysial antibodies
The invention discloses a recombinant anti-PD-L1 monoclonal antibody, relates to the technical field of biological medicines, and is used for providing an effective treatment medicine for patients with advanced or metastatic cancers, in particular to the patients with ineffective or drug-resistant treatment by an existing anti-PD-L1 medicine. The complementarity determining region of the antibodyhas sequences shown in SEQ ID NO: 1 to SEQ ID NO: 6. Compared with an existing anti-PD-L1 drug, the antibody has a unique binding epitope, and is better in affinity to human PD-L1 and better in tumorinhibition effect.
Owner:SHANGHAI ZHANGJIANG BIOTECH
Spinosyn derivative as argininosuccinate synthetase activator and application of spinosyn derivative
ActiveCN111632061AGood antitumor effectOrganic active ingredientsMetabolism disorderArgininosuccinate Synthetase 1Enzyme activator
The invention discloses spinosyn A and a derivative thereof as an activator of argininosuccinate synthetase 1 (ASS1) and an activator of mutant argininosuccinate synthetase ASS1G362V and application of the Spinosyn A and the derivative thereof. The spinosyn derivative has a structural general formula (I). The spinosyn and the derivative thereof are used as a medicine and an anti-tumor medicine fortreating I-type citrullinemia by activating the argininosuccinate synthetase 1 (ASS1) and the mutant argininosuccinate synthetase ASS1G362V in a targeted manner.
Owner:CENT SOUTH UNIV
Pirarubicin or pirarubicin hydrochloride lipid nano granule and preparation method thereof
InactiveCN101352418ALow toxicityIncrease concentrationOrganic active ingredientsAntineoplastic agentsLipid formationCancer cell
The invention provides a pirarubicin hydrochloride or pirarubicin lipid nanoparticle which can be used for injection and oral administration and a preparation method thereof; the invention is characterized that in the existence of a surface active agent, a carrier material packs the pirarubicin hydrochloride or pirarubicin and the prepared lipid nanoparticle has small particle size, high entrapment rate, good stability and low toxicity. The prepared lipid nanoparticle of the invention can enhance the targeting function to cancer cells, improve the inhibiting and killing function of the pirarubicin to tumor cells and improve the curative effect; the various preparation method of the pirarubicin or the pirarubicin hydrochloride lipid nanoparticle related by the invention has simple preparation technique and low cost and is applicable to industrial production on a large scale.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Pyrimidine derivative with anticancer effect
InactiveCN111249283AGood antitumor effectEnhanced inhibitory effectOrganic active ingredientsOrganic chemistryAnticarcinogenic EffectCancer prevention
Owner:SICHUAN UNIV
Interferon alpha and antisense K-ras RNA combination gene therapy
InactiveUS20050260167A1Increased cell deathEasy to solveBiocideSugar derivativesAbnormal tissue growthWhole body
An antiproliferative effect of IFN-α gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-α to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect of the invention relates to targeting the characteristic genetic aberration, K-ras point mutation, in pancreatic cancer, and that the expression of antisense K-ras RNA significantly suppresses the growth of pancreatic cancer cells. When these two gene therapy strategies are combined, the expression of antisense K-ras RNA significantly enhanced IFN-α-induced cell death (1.3-3.5 fold), and suppressed subcutaneous growth of pancreatic cancer cells in mice. The invention also relates to a method of suppressing pancreatic cancer cells using double strand RNA formed by antisense and endogeneous K-ras RNA in combination with the anti-tumor activity of IFN-α. The invention relates to the combination of IFN-α and antisense K-ras RNA as an effective gene therapy strategy against pancreatic cancer. The invention also relates to a method of treating pancreatic cancer cells disseminated throughout the body by administering the inventive combination to localized pancreatic cancer cell tumor. The invention also relates to inducing indirect immunological antitumor activity to provide systemic immunity against pancreatic cancer cells.
Owner:HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND
Single light-activated nano particle and preparation method and application thereof
ActiveCN110302379AExcellent light-to-heat conversion performanceStrong light-to-heat conversion abilityPhotodynamic therapyAntineoplastic agentsCell toxicityPhase-change material
The invention provides a single light-activated nano particle and a preparation method and application thereof, and belongs to the technical field of medicine. The single light-activated nano particlecomprises a hollow bismuth selenide nano particle, a phase-change material and a radical initiator, wherein the phase-change material and the radical initiator are loaded in the hollow bismuth selenide nano particle. The single light-activated nano particle is in laser radiation, absorbed light energy is converted to hyperthermia, cancer cells are directly killed, the phase-change material further can be prompted to melt, so that the radical initiator is released and split, generated free radical can cause cell membrane lipid peroxidation, glutathione is consumed, DNA is damaged, and thus thecancer cells are removed further. By detecting in vitro cytotoxicity and in vivo anti-cancer function, it is proved that the single light-activated nano particle has superior tumor killing capacity,and efficient photo-thermal and photodynamic combined therapy is realized through the hyperthermia and hyperthermia cascade activated free radical.
Owner:NANKAI UNIV
Anti-tumor fusion protein as well as encoding gene and application thereof
InactiveCN104151432ATargetedRetain phagocytosisPeptide/protein ingredientsHybrid peptidesTuftsinWilms' tumor
The invention provides an anti-tumor fusion protein. The fusion protein has the following first-grade amino acid sequence structure: EGFR specifically targeted oligopeptide-linking peptide 1-lidamycin apoprotein-linking peptide 2-(tuftsin)n, wherein the EGFR specifically targeted oligopeptide-linking peptide has an amino acid sequence as shown in SEQ ID No.1, the lidamycin apoprotein has an amino acid sequence as shown in SEQ ID No.2, the tuftsin has an amino acid sequence as shown in SEQ ID No.3, and n is equal to 1-3. The fusion protein is a novel protein targeting EGFR and containing LDP and Tuftsin, not only retains the phagocytosis promoting effect of the Tuftsin, but also has targeting property and has a favorable anti-tumor effect in an animal body. The invention also provides an encoding gene of the fusion protein, a strengthened fusion protein assembled with a lidamycin chromophore and application of the anti-tumor fusion protein and the strengthened fusion protein in preparation of medicines.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Paeonal injection emulsion for anti-tumor and its preparing method
InactiveCN1682753AQuick effectHigh drug contentOrganic active ingredientsAntineoplastic agentsEmulsionSide effect
The present invention relates to paeonal injection emulsion for treating tumor and is preparation process. The emulsion consists of liposoluble paeonal and water soluble glossy ganoderma polysaccharide as effective components. The paeonal injection emulsion has high and fast curative effect on tumor, high medicine content, and less toxic side effect.
Owner:SHANDONG ACAD OF CHINESE MEDICINE
LHRH-bonded amphiphilic biodegradable polymer, preparation method and application
ActiveCN102659950AReduce dosageReaction is easy to controlPowder deliveryCarrier-bound/immobilised peptidesGlycinePolymer science
Owner:CHANGZHOU INST OF ENERGY STORAGE MATERIALS &DEVICES
Anti-tumor composition in ganoderma lucidum spore oil and preparation method thereof
ActiveCN103054910AImprove anti-tumor effectGood antitumor effectAntineoplastic agentsPlant ingredientsSporelingFreeze-drying
The invention discloses an anti-tumor composition in ganoderma lucidum spore oil and a preparation method thereof. The method comprises the following steps: extracting the ganoderma lucidum spore oil from wall-broken ganoderma lucidum spore powder; adding organic solvents such as petroleum ether and ethanol and purified water to extract; concentrating extracted lower-layer liquor; carrying out column separation on the concentrated liquor by using a macroporous resin column; carrying out gradient eluting by purified water, 50% ethanol and ethanol with concentration greater than or equal to 75%; and collecting the last eluate and freeze-drying the eluate to obtain the anti-tumor composition. The composition obtained by the invention can inhibit external and internal tumor cell growth, and the anti-tumor rate reaches over 56.3%.
Owner:福建仙芝楼生物科技有限公司
Sulfydryl-containing zwitterionic polypeptide modified doxorubicin derivative, nano-micelle and preparation methods of doxorubicin derivative and nano-micelle
ActiveCN111643678AQuick releaseGood pH responseOrganic active ingredientsNanomedicineFluoroacetic acidTrifluoroacetic acid
Owner:YANSHAN UNIV
Novel 5-fluorouracil derivative
ActiveUS20120232103A1Improve anti-tumor effectEliminate side effectsBiocideOrganic active ingredientsAnticarcinogenBULK ACTIVE INGREDIENT
The present invention provides a novel antimetabolic anticancer agent that has an excellent balance between antitumor effect and toxicity. Specifically, the present invention provides a medicament containing, as an active ingredient, a 5-fluorouracil derivative represented by Formula (I) or a salt thereof:wherein R1 represents a hydrogen atom or a protecting group of a hydroxy group, R2 represents a lower alkoxy-lower alkyl group or a tetrahydrofuranyl group, X represents a carbon atom or a nitrogen atom, and Y represents a halogen atom or a cyano group.
Owner:DELTA FLY PHARMA
Chimeric antigen receptor comprising costimulatory receptor and application thereof
ActiveCN110615842AIncrease lethalityImprove acceleration performanceVirusesPeptide/protein ingredientsSide effectReceptor
Owner:SHANGHAI LONGYAO BIOTECH CO LTD
Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine
InactiveCN101229362AEnhance immune functionStrong immune functionPeptide/protein ingredientsAntineoplastic agentsSerum Thymic FactorSide effect
The invention discloses applications of serum thymus factor (FTS) in preparation of anti-tumor medicines, protective medicine or immunity intensified medicines for physical treatment and chemical treatment of tumor. Experimental results reveal that all groups of tumor-bearing mice and W256 rat fed with medicines are significantly different from groups fed with physiological saline and the tumor inhibition rates of all the groups fed with the medicines are more than 30 percent, thus confirming the tumor inhibition effect of the FTS. The FTS can also enhance the immunity activity and strengthen the immunity function of living organisms in a plurality of aspects; the FTS has no toxicity and less side effects; the effective wide dose scope and wide safety range. The FTS has obvious protective function to immunity indexes of living organisms, which is discovered in the study of the protective medicines for the physical and chemical treatment medicines of tumor. Therefore, the FTS can provide a new target and development for the clinical treatment of tumor.
Owner:中国生化制药工业协会
Nano-medicine, preparation method thereof and application of nano-medicine
ActiveCN110840860ARealize the combinationAchieving a sensitizing effectOrganic active ingredientsEnergy modified materialsCalcium biphosphateCalcium pidolate
The invention provides a nano-medicine, a preparation method thereof and an application of the nano-medicine. The nano-medicine comprises a calcium phosphate substrate, a chemotherapy medicine, a photo-thermal agent and an autophagy inhibitor, the chemotherapy medicine is sealed in the calcium phosphate substrate, the surface of the calcium phosphate substrate is modified by the photo-thermal agent, and the autophagy inhibitor is loaded into a pore of the photo-thermal agent. According to the nano-medicine, chemotherapy and thermotherapy are combined, calcium phosphate serves as a rigid substrate, the chemotherapy medicine and the photo-thermal agent are sealed in the rigid substrate of the calcium phosphate, the autophagy inhibitor of a cell is loaded on the rigid substrate, so that chemotherapy and thermotherapy effects can be improved by inhibiting autophagy, and tumor treatment effects are improved.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA
Fabrication method and application of cellulose membrane of a drug loading breast cancer-targeting magnetic nanoparticles
ActiveCN106310256AImprove stabilityGood dispersionOrganic active ingredientsEnergy modified materialsTumor targetingFreeze-drying
The invention discloses a fabrication method of cellulose membrane of a drug loading breast cancer-targeting magnetic nanoparticles. The method includes the following steps: 1. Grant the folic acid of optical activity by chemical modification, fix the prepared acid on the magnetic hydrogel, which then is be used to absorb hematoporphyrin monomethyl and cancer therapeutic drug, and finally obtain the tumor-targeting nano-drug; 2. Produce cellulose membrane by cultivating acetobacter xylinum and static fermentation, add the tumor-targeting nano-drug solution made in step 1 into the container for the cellulose membrane under dark condition until it's submerged, and carry out vacuum freeze drying after processed by the oscillator. The cellulose membrane of a drug loading tumor-targeting magnetic nanoparticles has high efficient in targeting the breast caner cell and suppressing its growth. At the same time, it can significantly reduce the dosage of conventional photosensitizer. In addition, the transdermal drug delivery would enhance the the drug effects on caner, realizing the controlled-release of the drug and largely lowering the toxic and side effects to healthy tissues.
Owner:SOUTH CHINA NORMAL UNIVERSITY
Solamargine liposome, preparation method and usage thereof
ActiveCN102000028AGood biocompatibilityNo immunosuppressive effectOrganic active ingredientsDigestive systemKhasianineCholesterol
The invention relates to solamargine liposome, which is characterized in that the liposome comprises the following raw materials: 1 part by weight of solamargine, 8 to 80 parts by weight of phospholipid, 2 to 20 parts by weight of cholesterol and 1 to 10 parts by weight of emulsifier. The invention also discloses a preparation method of the solamargine liposome. The invention has the advantages that the solamargine is coated between the two phospholipid layers of the liposome so that the water solubility is enhanced; the physical stability of the solamargine liposome is good; and the solamargine liposome can be stored for a longer time. The preparation method of the solamargine liposome is simple and mature, and is convenient to industrial production.
Owner:JIANGSU KANION PHARMA CO LTD
Sodium new houttuyfonate and application of combination of sodium new houttuyfonate and cis-platinum in preparation of antitumor drugs
ActiveCN112336744AImprove anti-tumor effectGood antitumor effectInorganic active ingredientsAntineoplastic agentsSodium new houttuyfonateDisease
The invention provides sodium new houttuyfonate and application of sodium new houttuyfonate and cis-platinum in treatment of colon cancer, breast cancer, lymphoma, melanoma, lung cancer and other malignant tumors. A MTT method and a CCK-8 method are adopted to correspondingly determine sodium new houttuyfonate and inhibition effects of sodium new houttuyfonate and cis-platinum combined drug on various tumor cells (including SW620, A375, MCF-7, A549 and raji), and tests find that sodium new houttuyfonate and sodium new houttuyfonate and cis-platinum combined drug have significant inhibition effects on various tumor cells. Moreover, the combined medication shows an addition or synergistic effect, so that valuable theoretical and data support is provided for clinical treatment of malignant tumor diseases.
Owner:河南省医药科学研究院 +1
Application of ligand antrum mucosal protein-18(AMP-18) of laminin receptor in treatment of tumor
InactiveCN102827266AGood antitumor effectPeptide/protein ingredientsAntineoplastic agentsElastin laminin receptorDrug
The invention provides a ligand antrum mucosal protein-18(AMP-18) of a laminin receptor (LR), which has an amino acid sequence as shown in SEQ ID No.1 in a sequence table. The ligand antrum mucosal protein-18(AMP-18) can bind with LR on the surface of gastric epithelial cells to inhibit the growth of stomach cancer cells and can be used to prepare drugs for treating tumor.
Owner:BEIJING PROTEIN INNOVATION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap